Sequential treatment of deep fungal infections with amphotericin B deoxycholate and amphotericin B colloidal dispersion
- 45 Downloads
- 3 Citations
Abstract
Amphotericin B colloidal dispersion (ABCD) is a novel lipid formulation of amphotericin B designed to diminish toxic effects of the drug. In the following report, nine cases of suspected (n=4) and proven (n=5) deepCandida infection, treated sequentially with amphotericin B deoxycholate and ABCD, are presented. The treatment was successful in seven cases. During treatment with amphotericin B deoxycholate, a rise in serum creatinine was observed in seven patients, hypokalemia in five, and metabolic acidosis in four. After replacing amphotericin B deoxycholate with ABCD, laboratory parameters improved in four of the seven patients with increased creatinine, in four of the five patients with hypokalemia, and in two of the four patients with metabolic acidosis. Infusion-related rigors were observed in four patients receiving amphotericin B deoxycholate and in one patient treated with ABCD. Reversible elevation of liver enzymes was found in one patient receiving ABCD. In this study ABCD proved less toxic than amphotericin B deoxycholate. The efficacy of ABCD alone cannot be assessed because of previous treatment with amphotericin B deoxycholate, but sequential treatment of deepCandida infections with amphotericin B deoxycholate and ABCD seems to be an effective therapeutic modality, especially in patients requiring prolonged administration of amphotericin B.
Keywords
Creatinine Fungal Infection Amphotericin Liver Enzyme Metabolic AcidosisPreview
Unable to display preview. Download preview PDF.
References
- 1.Rex JH, Bennett JE, Sugar AM, Pappas PG, van den Horst CM, Edwards JE, Washburn RG, Scheid WM, Karchmer AW, Dine AP, Levenstein MJ, Webb D, for the Candidaemia Study Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group: A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. New England Journal of Medicine 1994, 331: 1325–1330.Google Scholar
- 2.Anaissie E, Bodey GP, Kantarjian H, David C, Barnett K, Bow E, Defelice R, Downs N, File T, Karam G, Potts D, Shelton M, Sugar A: Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B treatment. American Journal of Medicine 1991, 91: 142–150.Google Scholar
- 3.Rex JH, Pfaller MA, Barry AL, Nelson PW, Webb CD: Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. Antimicrobial Agents and Chemotherapy 1995, 39: 40–44.Google Scholar
- 4.Rex JH, Rinaldi MG, Pfaller MA: Resistance ofCandida species to fluconazole. Antimicrobial Agents and Chemotherapy 1995, 39: 1–8.Google Scholar
- 5.Johnson EM, Warnock DW: Azole drug resistance in yeast. Journal of Antimicrobial Chemotherapy 1995, 36: 751–755.Google Scholar
- 6.Khoo SH, Bond J, Denning DW: Administering amphotericin B — a practical approach. Journal of Antimicrobial Chemotherapy 1994, 33: 203–213.Google Scholar
- 7.Guo LSS, Fielding RM, Lasic DD: Novel antifungal drug delivery: stable amphotericin B-cholesteryl sulphate discs. International Journal of Pharmacokinetics 1991, 75: 45–59.Google Scholar
- 8.Fromtling RA: Amphotericin B cholesterol sulfate complex. Drugs of the Future 1993, 18: 303–306.Google Scholar
- 9.DeMarie S, Janknegt R, Bakker-Woudenberg IAJM: Clinical use of liposomal and lipid complexed amphotericin B. Journal of Antimicrobial Chemotherapy 1994, 33: 907–916.Google Scholar
- 10.Mills W, Chopra R, Linch DC, Goldstone AH: Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single center experience of 133 episodes in 116 patients. British Journal of Hematology 1994, 86:754–760.Google Scholar
- 11.Ringden O, Andstrom E, Remberger M, Svahn BM, Tollemar J: Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporin. Bone Marrow Transplantation 1994, 14, Supplement 5: 10–14.Google Scholar
- 12.Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC: Candidemia in a tertiary care hospital: epidemiology, risk factors and predictors of mortality. Clinical Infectious Diseases 1992, 15: 414–421.Google Scholar
- 13.Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP: Hospital-acquired candidemia. The attributable mortality and excess length of stay. Archives of Internal Medicine 1988, 148: 2642–2645.Google Scholar
- 14.Oppenheim BA, Herbrecht R, Kusne S: The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clinical Infectious Diseases 1995, 21: 1145–1153.Google Scholar
- 15.Bowden RA, Cays M, Gooley T, Mamelok RD, van Burik JA: Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. Journal of Infectious Diseases 1996, 173:1208–1215.Google Scholar
- 16.Fisher MA, Talbot GH, Maislin G, McKeon BP, Tynan KP, Strom BL: Risk factors for amphotericin B associated nephrotoxicity. American Journal of Medicine 1989, 87: 547–552.Google Scholar
- 17.Amantea MA, Bowden RA, Forrest A, Working PK, Newman MS, Mamelok RD: Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants. Antimicrobial Agents and Chemotherapy 1995, 39: 2042–2047.Google Scholar
- 18.Dietze R, Fagundes SM, Brito EF, Milan EP, Feitosa TF, Suassuna FA, Fonschiffrey G, Ksionski G, Dember J: Treatment of kala-azar in Brazil with Amphocil (amphotericin B cholesterol dispersion) for 5 days. Transactions of the Royal Society of Tropical Medicine and Hygiene 1995, 89: 309–311.Google Scholar
- 19.Meunier F: Candidiasis. European Journal of Clinical Microbiology & Infectious Diseases 1989, 8: 438–447.Google Scholar
- 20.Gallis HA, Drew RH, Pickard WW: Amphotericin B: 30 years of clinical experience. Reviews of Infectious Diseases 1990, 12: 308–329.Google Scholar